Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02494804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Trial Details
NCT Number NCT02494804
Lead Sponsor The First People's Hospital of Changzhou
Conditions
(from sponsor)		 Cytokine-Induced Killer Cells, Milignant Gliomas
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov